Late Stage and Commercial Development
Agilent oligo contract manufacturing currently produces six commercially approved, active pharmaceutical ingredient (API) molecules. As shown by years of successful inspections, Agilent’s quality management system, cGMP manufacturing sites, and analytical capabilities are compliant with FDA requirements.
The large-scale Agilent facility in Frederick produces multikilogram lots of oligo APIs for late-stage clinical trials and commercialization. To increase batch sizes and accommodate more programs, Agilent launched a second manufacturing train in 2023. Future expansion is additionally planned for 2027.
The large-scale Agilent facility in Frederick produces multikilogram lots of oligo APIs for late-stage clinical trials and commercialization. To increase batch sizes and accommodate more programs, Agilent launched a second manufacturing train in 2023. Future expansion is additionally planned for 2027.